Challenges faced when identifying patients for combination immunotherapy

Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma

(2017) Christine G. Kohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology

(2017) Laura C. Cappelli et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

(2017) Whijae Roh et al.   Science Translational Medicine

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States

(2017) Jingshu Wang et al.   Journal of Managed Care & Specialty Pharmacy

Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient

(2016) B. R. Gastman et al.   ANNALS OF ONCOLOGY

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study

(2016) Yasuhiro Nakamura et al.   JOURNAL OF DERMATOLOGY

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

(2016) Jeffrey S Weber et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma

(2014) Evan J. Lipson et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice

(2014) Clément Cochain et al.   PLoS One

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity

(2014) L. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy

(2013) D. Ng Tang et al.   Cancer Immunology Research

Shared Decision Making: A Model for Clinical Practice

(2012) Glyn Elwyn et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma

(2011) Katelyn T. Byrne et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients

(2009) T. Schwaab et al.   CLINICAL CANCER RESEARCH